Overview

Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)

Status:
Completed

Trial end date:
2010-06-01

Target enrollment:

Participant gender:

Summary

The primary objective of Part I of the study is to determine tumor response rate of sequential topoisomerase targeting with irinotecan/oxaliplatin followed by etoposide /carboplatin in chemotherapy-naïve patients with extensive small cell lung cancer. The primary objective of Part II of the study is to determine the objective tumor response rate of irinotecan/oxaliplatin in patients with either refractory disease or who have relapsed to first line chemotherapy or chemoradiotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

University of Alabama at Birmingham

Collaborators:

Amgen
Sanofi-Synthelabo

Treatments:

Camptothecin
Carboplatin
Etoposide
Etoposide phosphate
Irinotecan
Oxaliplatin